Leptomeningeal Disease
14
7
8
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
21.4%
3 terminated out of 14 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (14)
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
Non Interventional German Leptomeningeal Disease Register
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
B7-H3.CD28Z.CART in CNS Neoplasms
Study Assessing QBS72S For Treating Brain Metastases
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC